Results 131 to 140 of about 56,865 (248)
Hepatic Arterial Buffer Response: Pathologic Evidence in Non-Cirrhotic Human Liver with Portal Vein Thrombosis [PDF]
, 2016 poster abstractHepatic arterial buffer response (HABR) is the ability of the hepatic artery (HA) to compensate for changes in portal flow. Experimentally, occlusion of the portal vein leads to compensatory increase in HA flow with minimal parenchymal ...
Kwo, Paul Y. +5 more
core
Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders
International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 259-271, April 2026.ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley +1 more source
International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 392-401, April 2026.ABSTRACT Introduction D‐dimers are produced by lysis of cross‐linked fibrin. In children, D‐dimer testing is used to evaluate disseminated intravascular coagulation (DIC) and some inflammatory states, but its use is not validated for screening or ruling out suspected venous thromboembolic events (VTE).
Rabab Al Dawood +4 more
wiley +1 more source
Thrombosis JournalObjective To evaluate the risk factors of liver cirrhosis complicated with portal vein thrombosis and the efficacy and safety of anticoagulant therapy.
Le Zhang +5 more
doaj +1 more source
Hepatocarcinoma with tumor thrombus occupying the right atrium and portal vein in a patient with hereditary hemochromatosis and liver cirrhosis [PDF]
, 2018 We present the case of a 46-year old patient with Child-Pugh class C cirrhosis with MEDL-Score 16, and hepatocellular carcinoma invading the inferior vena cava and the right atrium.
Breaban, Iulia +11 more
core +1 more source
Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD
Liver International, Volume 46, Issue 4, April 2026.ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease.
Alex E. Henney +4 more
wiley +1 more source
Preventing First and Further Decompensation in Advanced Chronic Liver Disease
Liver International, Volume 46, Issue 4, April 2026.ABSTRACT Advanced chronic liver disease (ACLD) remains a major cause of global morbidity and mortality. Preventing hepatic decompensation—both the first event and subsequent recurrences—has become a central therapeutic goal to prolong survival. The transition from the compensated phase (cACLD) to the decompensated phase (dACLD) is driven by clinically ...
Leonardo Corrêa Süffert +2 more
wiley +1 more source
Thrombosis of a Superior Mesenteric Vein Aneurysm: Transarterial Thrombolysis and Transhepatic Aspiration Thrombectomy [PDF]
, 2018 We report the case of a 31-year-old woman presenting with abdominal pain due to acute thrombosis of a superior and inferior mesenteric vein aneurysm, which was treated by a combination of arterial thrombolysis and transhepatic thrombus aspiration. At the
Crook, D.W. +4 more
core
Liver International, Volume 46, Issue 4, April 2026.ABSTRACT Background and Aims Extrahepatic portal vein obstruction (EHPVO) is among the main causes of childhood portal hypertension. We analysed nationwide long‐term outcomes of EHPVO in relation to various management options. Methods In total, 62 consecutive patients with EHPVO diagnosed between 1987 and 2023 were followed up through hospital records ...
Topi Luoto +2 more
wiley +1 more source
Pancreatic transplantation at the University of Pittsburgh. [PDF]
, 2004 Campath-1H preconditioning with tacrolimus monotherapy is an effective immunosuppressive regimen for pancreas transplantation, with acceptable patient and graft survival rates early after transplantation.
Abu-Elmagd, K +12 more
core